VIA
LBRX

Virtus Investment Advisers’s LB Pharmaceuticals LBRX Stock Holding History

Virtus Investment Advisers’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Buy
+11,513
New +$338K 0.09% 319

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Virtus Investment Advisers's LBRX Position: Q2 2026 in Review

Virtus Investment Advisers opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 11,513 shares worth $374K. The stake represents 0.09% of the portfolio and ranks #319 among its holdings.

115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Virtus Investment Advisers held 11,513 shares of LB Pharmaceuticals worth $374K as of Q2 2026.
  • LB Pharmaceuticals was a new Virtus Investment Advisers position in Q2 2026.
  • LB Pharmaceuticals made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #319 holding.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.